In one paragraphArticle in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
15 authors.
Meng-Yen LiDepartment of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Paula RestrepoDepartment of Dermatology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pooja FloraDepartment of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gil Segal-DalalThe Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Science, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Eldad SilbersteinDepartment of Plastic Surgery, Soroka University Medical Center, Faculty of Health Science, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Xiaotao ZhangDivision of Liver Diseases, Department of Medicine, Translational Epidemiology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-3968-5030 Funding
Skin Biology and Diseases Resource-based Center at Mount SinaiP30AR079200 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elena Ezhkova · 2021 to 2026
$5.2MToward Understanding the Role of the Polycomb Complex in Skin ControlR01AR069078 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EZHKOVA, ELENA · 2016 to 2024
$4.4MRoles and regulation of transcriptional reprogramming in squamous carcinogenesisR01CA266656 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Markus Schober · 2022 to 2026
$2.4MPost-translational SOX2 modification - a regulatory switch between self-renewal and differentiation in squamous cell carcinomaR01CA248175 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SCHOBER, MARKUS · 2021 to 2025
$2.2MCellular and Molecular Mechanisms Underlying Merkel Cell Loss and RegenerationR01AG089916 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Elena Ezhkova, Hongzhen Hu · 2024 to 2026
$1.8MCancer Cell-Extrinsic and Intrinsic Regulators of TumorigenesisK08CA263187 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI JI, ANDREW · 2021 to 2025
$1.1MResearch Training in Systems Skin BiologyT32AR082315 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Patrick Brunner, Sarah E. Millar · 2023 to 2026
$1.0MElucidating the Functions of Epigenetic Regulators in Control of Skin Stem CellsR00AR057817 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI EZHKOVA, ELENA · 2011 to 2013
$735kNCI NIH HHS K08 CA263187NCI NIH HHS R01 CA248175NCI NIH HHS R01 CA266656NIAMS NIH HHS P30 AR079200NIAMS NIH HHS R00 AR057817NIAMS NIH HHS R01 AR069078NIAMS NIH HHS T32 AR082315NIA NIH HHS R01 AG089916U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) P30AR079200U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) R01AR069078
6 · The paper itselfAbstract
Squamous cell carcinomas (SCCs) are common epithelial malignancies frequently associated with EZH2 upregulation, which correlates with aggressive growth and poor prognosis. EZH2 functions as the catalytic subunit of Polycomb repressive complex 2 (PRC2), which deposits the repressive H3K27me3 histone mark, yet PRC2 function in SCC pathogenesis remains unresolved. Here, we uncover a paradox: although EZH2 is elevated, the PRC2-catalyzed H3K27me3 is profoundly reduced in human SCC and complementary murine models. Mechanistically, we identify that oncogenic Ras signaling causes degradation of the PRC2 subunit EED, destabilizing PRC2 and depleting H3K27me3. Loss of EED reprograms keratinocytes into an aggressive tumor-specific cell state and induces paracrine factors that remodel the tumor microenvironment, driving metastasis. Remarkably, reintroducing EED suppresses tumor growth via restoring PRC2 integrity and H3K27me3 levels, revealing the reversibility of this epigenetic collapse. These findings link oncogenic signaling to epigenetic reprogramming and uncover PRC2 reconstitution as a potential therapeutic option in epithelial cancers.
Indexed as
Carcinoma, Squamous CellPolycomb Repressive Complex 2AnimalsCell Line, TumorEnhancer of Zeste Homolog 2 ProteinEpigenesis, GeneticGene Expression Regulation, NeoplasticHistonesHumansKeratinocytesMiceProteolysisSignal TransductionTumor MicroenvironmentEED protein, humanEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistonesPolycomb Repressive Complex 2
Identifiers
PMID42443217
PMCPMC13486728
What Socratic holds
Textmetadata
Read underepoch 390